Instituto de Investigaciones Clinicas Quilmes

Quilmes, Buenos Aires B1878GEG

1 studies enrolling now · 17 studies all time

What they study most

Atherosclerotic Cardiovascular Disease, Cardiovascular Disease, Chronic Cutaneous Lupus Erythematosus, Primary Sjogrens Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Subacute Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE), Ulcerative Colitis

Studies at this site

• A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines — Recruiting now
• A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus — Running, not enrolling
• ABTECT - Maintenance — Running, not enrolling
• A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome — Running, not enrolling
• Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial — Running, not enrolling
• A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD) — Completed
• ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 — Completed
• An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) — Completed
• Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) — Completed
• Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis — Completed
• Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease — Completed
• A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) — Stopped early
• A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II) — Completed
• An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis — Completed
• A Phase II Study of M2951 in SLE — Stopped early
• Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis — Completed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early